2022
Outcomes for Organ Preservation with Chemoradiation Therapy for T4 Larynx and Hypopharynx Cancer
Eita A, Mohamed N, Rybkin A, Kang J, Fiasconaro M, Zhigang Z, Zakeri K, Yu Y, Sadaka E, Sherman E, Dunn L, Cracchiolo J, Wong R, Cohen M, Lee N. Outcomes for Organ Preservation with Chemoradiation Therapy for T4 Larynx and Hypopharynx Cancer. The Laryngoscope 2022, 133: 1138-1145. PMID: 35801573, PMCID: PMC10547133, DOI: 10.1002/lary.30279.Peer-Reviewed Original ResearchConceptsUnivariate analysisLocoregional failureT4 laryngealNonoperative managementHypopharyngeal cancerRadiation therapyPercutaneous endoscopic gastrostomy tubeHypopharynx cancer patientsYear OS ratesDisease-free survivalNon-surgical managementHypopharynx groupsInoperable diseaseLast followUnresectable diseaseChemoradiation therapyNodal statusGastrostomy tubeHypopharynx cancerOS ratesStage T4Cancer patientsFunctional outcomeTracheostomy tubeOrgan preservation
2020
Clinical Outcomes and Toxicities in Oropharyngeal Cancer (OPC) Patients Treated with Proton Therapy: A Single Institutional Experience
Kitpanit S, Lee A, Fan D, Fan M, Wang H, Mohamed N, Spielsinger D, Gelblum D, Sherman E, Dunn L, Boyle J, Wong R, Cohen M, Kang J, Tsai C, McBride S, Zakeri K, Chen L, Yu Y, Riaz N, Lee N. Clinical Outcomes and Toxicities in Oropharyngeal Cancer (OPC) Patients Treated with Proton Therapy: A Single Institutional Experience. International Journal Of Radiation Oncology • Biology • Physics 2020, 106: 1152-1153. DOI: 10.1016/j.ijrobp.2019.11.231.Peer-Reviewed Original ResearchTemporal Lobe Necrosis in Head and Neck Cancer Patients after Proton Therapy to the Skull Base
Kitpanit S, Lee A, Pitter KL, Fan D, Chow JCH, Neal B, Han Z, Fox P, Sine K, Mah D, Dunn LA, Sherman EJ, Michel L, Ganly I, Wong RJ, Boyle JO, Cohen MA, Singh B, Brennan CW, Gavrilovic IT, Hatzoglou V, O'Malley B, Zakeri K, Yu Y, Chen L, Gelblum DY, Kang JJ, McBride SM, Tsai CJ, Riaz N, Lee NY. Temporal Lobe Necrosis in Head and Neck Cancer Patients after Proton Therapy to the Skull Base. International Journal Of Particle Therapy 2020, 6: 17-28. PMID: 32582816, PMCID: PMC7302730, DOI: 10.14338/ijpt-20-00014.1.Peer-Reviewed Original ResearchMagnetic resonance imagingRadiation-naïve patientsDose-volume parametersSkull baseNeck cancerTemporal lobeCutoff valueMaximum doseProton therapyAdverse Events v5.0Common Terminology CriteriaTemporal lobe necrosisNeck cancer patientsDose-volume factorsTerminology CriteriaMedian followBrain necrosisMedian timeClinical parametersCancer patientsMedical recordsGrade 3Necrosis rateField of radiationPatients
2015
Pelvic Nodal Dosing With Registration to the Prostate: Implications for High-Risk Prostate Cancer Patients Receiving Stereotactic Body Radiation Therapy
Kishan AU, Lamb JM, Jani SS, Kang JJ, Steinberg ML, King CR. Pelvic Nodal Dosing With Registration to the Prostate: Implications for High-Risk Prostate Cancer Patients Receiving Stereotactic Body Radiation Therapy. International Journal Of Radiation Oncology • Biology • Physics 2015, 91: 832-839. PMID: 25752398, DOI: 10.1016/j.ijrobp.2014.11.035.Peer-Reviewed Original ResearchMeSH KeywordsAnatomic LandmarksCone-Beam Computed TomographyFiducial MarkersHumansLymph NodesLymphatic IrradiationMaleMovementOrgan SizePelvic BonesPelvisProstateProstatic NeoplasmsRadiosurgeryRadiotherapy DosageRadiotherapy Planning, Computer-AssistedRadiotherapy, Image-GuidedRectumSeminal VesiclesUrinary BladderConceptsNodal coverageCone-beam CTKilovoltage cone-beam CTHigh-risk prostate cancer patientsHigh-risk prostate cancerNodal clinical target volumeStereotactic body radiation therapyBladder-filling protocolPelvic lymph nodesMajority of patientsSubset of patientsRadiation therapy regimenProstate cancer patientsBody radiation therapyClinical target volumeAverage V100Multimodality bladderSBRT regimenStrict bladderLymph nodesPelvic nodalTherapy regimenCancer patientsProstate cancerRadiation therapy